University of California San Francisco

Adam Mohamed 144
Mohamed Abdelgadir Adam, MD

Assistant Professor of Surgery 
Division of Surgical Oncology

Address

550 16th Street, #6411
San Francisco, CA 94158
United States

    Biography

    Mohamed Abdelgadir Adam is an assistant professor in the Division of Hepatobiliary and Pancreatic Surgery. He is a cancer surgeon who treats gastrointestinal tumors and specializes in the treatment of cancers of the pancreas and bile ducts. Dr. Adam has special expertise in robotic minimally invasive pancreato-biliary surgery, including robotic pancreaticoduodenectomy (Whipple procedure). Additionally, he has experience in regional treatment strategies for metastatic cancers in the liver and the peritoneal cavity, including placement of hepatic infusion pumps for patients with unresectable (colorectal and intrahepatic cholangiocarcinoma) liver disease and cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

     

    Dr. Adam received his medical degree from the Faculty of Medicine and Health Sciences. He completed general surgery training at Duke University Medical Center in Durham, NC. He continued his training with a two-year fellowship in complex surgical oncology at the University of Pittsburgh Medical Center in Pittsburgh, PA. Dr. Adam also completed two research fellowships at Duke University.

     

    Dr. Adam’s research focuses on leveraging translational artificial intelligence and machine learning algorithms to optimize cancer patients’ treatment. He is a prolific researcher and has already authored over one hundred publications. He is a member of several professional societies. Dr. Adam already received many academic honors at Duke University and UCSF.

    Education

    Education

    MD: Faculty of Medicine and Health Sciences, Omdurman Islamic University, Sudan

    Residencies

    2018: General Surgery Residency, Duke University Medical Center

    Fellowships
    Complex General Surgical Oncology Fellowship
    End Year
    2020
    Postdoctoral Training

    2010: Postdoctoral Research Fellowship, Duke Institute for Genome Sciences & Policy, Durham, NC
    2016: Research Fellowship, Duke Clinical Research Institute, Durham, NC

    Board Certifications

    American Board of Surgery, General Surgery

    Clinical Expertise

    Robotic Minimally Invasive Whipple & Distal Pancreatectomy
    Bile Duct Cancer (Cholangiocarcinoma)
    Bile Duct Injuries
    Bile Duct Strictures
    Transplantation
    Choledochal Cysts
    Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Gallbladder Cancer
    Gastrointestinal Carcinoid Tumor
    Gastrointestinal Stromal Tumor (GIST)
    Liver Cysts
    Liver Metastases
    Pancreatic Cancer
    Pancreatic Cysts
    Pancreatic Neuroendocrine Tumors
    Stomach (Gastric) Cancer

    Foreign Languages Spoken

    Arabic

    Research Narrative

    Dr. Adam’s research focuses on leveraging translational artificial intelligence and machine learning algorithms to optimize cancer staging and treatment. He is a prolific researcher and has already authored over one hundred publications.

    Research Interests

    Leveraging translational artificial intelligence and machine learning in optimizing staging and management of gastrointestinal cancers. 
    Health Services Research

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 5
    1. ASO Visual Abstract: Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy-A Data-Driven, Machine Learning Approach to Augment Clinical Judgement.
      Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM| | View in PubMed
    2. Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Data-Driven, Machine Learning Approach to Augment Clinical Judgment.
      Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM| | View in PubMed
    3. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.
      Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH| | View in PubMed
    4. ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma.
      Adam MA, Glencer AC, Zureikat AH| | View in PubMed
    5. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
      Adam MA, Paniccia A| | View in PubMed